210 related articles for article (PubMed ID: 25073801)
1. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
Cho HY; Kyung MS
Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
[TBL] [Abstract][Full Text] [Related]
2. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
3. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
4. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
5. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
6. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors.
Lertkhachonsuk AA; Buranawongtrakoon S; Lekskul N; Rermluk N; Wee-Stekly WW; Charakorn C
J Obstet Gynaecol Res; 2020 Nov; 46(11):2287-2291. PubMed ID: 32830422
[TBL] [Abstract][Full Text] [Related]
7. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
9. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with misdiagnosis of frozen section of mucinous borderline ovarian tumor.
Zhang W; Jia S; Xiang Y; Yang J; Jia C; Leng J
J Int Med Res; 2019 Jan; 47(1):96-104. PubMed ID: 30198356
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma.
Cho HY; Kim K; Jeon YT; Kim YB; No JH
Med Sci Monit; 2013 Mar; 19():230-5. PubMed ID: 23539074
[TBL] [Abstract][Full Text] [Related]
14. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of CA19-9 in ovarian mature cystic teratoma.
Fan JT; Yan HQ; Malla S; Fan YJ; Xu H; Li DH; Liu Y
Clin Exp Obstet Gynecol; 2016; 43(4):522-525. PubMed ID: 29734540
[TBL] [Abstract][Full Text] [Related]
17. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
Zhang W; Wang L; Xin Z
Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
Chen JM; Gao HY; Wang Q; Li Q
Clin Exp Obstet Gynecol; 2016; 43(3):397-400. PubMed ID: 27328499
[TBL] [Abstract][Full Text] [Related]
20. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
